Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Daniel Kulp
Author Correction: Vaccination induces broadly neutralizing antibody precursors to HIV gp41 - Nature Immunology
Correction to: Nature Immunology https://doi.org/10.1038/s41590-024-01833-w, published online 30 May 2024 In the version of the article initially published, Steven Schultze’s surname appeared incorrectly (as Schulze) and has now been amended in the HTML and PDF versions of the article.
Vaccination induces broadly neutralizing antibody precursors to HIV gp41 - Nature Immunology
|
Abstract A key barrier to the development of vaccines that induce broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV) and other viruses of high antigenic diversity is the design of priming immunogens that induce rare bnAb-precursor B cells.
By Ivy Phung, Olivia K. Swanson, Chang-Chun D. Lee, Ester Marina-Zárate, Gabriel Ozorowski, Kimmo Rantalainen, Joel Allen, Sabyasachi Baboo, Oscar Rodriguez, Oscar Rodríguez Verified, Óscar Rodríguez Verified, Sunny Himansu, Swati Saha, Simone Pecetta, Ying-Cing Lin, Jordan Willis, Daniel Kulp, Christopher A. Cottrell, Oleksandr Kalyuzhniy, Erik Georgeson, Rama R. Amara, Elise Landais, Dennis R. Burton, Guido Silvestri, Corey T. Watson, James C. Paulson, Max Crispin, Gevorg Grigoryan, Andrew Ward, Devin Sok, Frederick W. Alt, Ian Wilson, Facundo D. Batista, Shane Crotty
|
Nature
Verified
Biomedical Transparency Summit (BMTS) 2024
The 2024 Biomedical Transparency Summit is the 6th annual thought leadership gathering of biomedical research funders, policymakers, government departments, journal editors & publishers, tech developers, biopharma, and academia.
Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers
Synthetic nanoparticles have attracted widespread interest for vaccine design, but how the immune system generates a response to multimeric nanoparticles remains unclear. Tokatlian et al. studied immunity generated by HIV envelope antigens arranged in either multivalent nanoparticle forms or as single monomers (see the Perspective by Wilson). The nanoparticle HIV immunogens triggered greater antibody responses compared with the monomeric forms.
Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers
Download and print this article for your personal scholarly, research, and educational use. Buy a single issue of Science for just $15 USD.
The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen
Despite decades of intensive research, HIV vaccines are unable to generate broadly neutralizing antibodies that are likely necessary for protection. One vaccine candidate, eOD-GT8, was designed to bait naive B cells that may be capable of producing antibodies similar to VRC01, a potent CD4-binding site–targeting antibody with breadth. Havenar-Daughton et al. inspected the potential of human naive B cells to recognize eOD-GT8, and isolated B cells that used similar genes as those used to make VRC01.
Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice
Antibodies hold great promise for HIV-1 prophylaxis because they can prevent infection in pre-clinical models even at low concentrations (Gautam et al., 2016xA single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Gautam, R., Nishimura, Y., Pegu, A., Nason, M.C., Klein, F., Gazumyan, A., Golijanin, J., Buckler-White, A., Sadjadpour, R., Wang, K. et al. Nature.
Global site-specific N-glycosylation analysis of HIV envelope glycoprotein
We devised a proteomics-based strategy to assess the degree of glycan processing and the degree of site occupancy of each glycosite, defined as the N-glycosylation sequon N-X-S/T (Fig. 1a). To this end, we used sequential treatment with two endoglycosidases common to glycoproteomics workflows to introduce novel mass signatures for peptides that contain the two types of glycans29,35,36.
[RESTART] [VOTE] Graduate Apache Beam
> [ X ] +1, Graduate Apache Beam from the Incubator. +1 Dan > On Dec 5, 2016, at 6:30 PM, Davor Bonaci wrote: > > Hi everyone, > Please vote on the draft resolution proposed by the Apache Beam PPMC below, > which establishes Apache Beam as a new top-level project at the Apache > Software Foundation, as follows: > > [ ] +1, Graduate Apache Beam from the Incubator. > [ ] +0, Don't care. > [ ] -1, Don't graduate Apache Beam from the Incubator because...
[VOTE] Graduate Apache Beam
> [ X ] Approve the proposed resolution +1 Dan > On Dec 5, 2016, at 1:28 PM, Davor Bonaci wrote: > > Hi everyone, > Please vote to approve/disapprove the draft resolution proposed by the > Apache Beam PPMC below, which establishes Apache Beam as a new top-level > project at the Apache Software Foundation, as follows: > > [ ] Approve the proposed resolution > [ ] Disapprove the proposed resolution > > Before voting, please see the corresponding discussion thread [1], and vote > only after you...
[DISCUSS] Apache Beam podling graduation readiness
> On Dec 4, 2016, at 1:20 AM, Roman Shaposhnik wrote: > > > Thanks -- that's very helpful information. > > One last question -- at a quick glance you're the only ASF member on > the PMC, correct? I’m also following Beam closely (and have submitted several pull requests working toward becoming a committer). Thus, there are at least 3 ASF members (with Stephan) that will be “keeping an eye on things”. :) That shouldn’t be a concern.
Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice
A major obstacle to a broadly neutralizing antibody (bnAb)–based HIV vaccine is the activation of appropriate B cell precursors. Germline-targeting immunogens must be capable of priming rare bnAb precursors in the physiological setting. We tested the ability of the VRC01-class bnAb germline-targeting immunogen eOD-GT8 60mer (60-subunit self-assembling nanoparticle) to activate appropriate precursors in mice transgenic for human immunoglobulin (Ig) loci.
Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice
A major obstacle to a broadly neutralizing antibody (bnAb)-based HIV vaccine is the activation of appropriate B cell precursors. Germline-targeting immunogens must be capable of priming rare bnAb precursors in the physiological setting. We tested the ability of the VRC01-class bnAb germline-targeting immunogen eOD-GT8 60mer to activate appropriate precursors in mice transgenic for human immunoglobulin loci.
[VOTE] Accept Beam into the Apache Incubator
+1 Dan > On Jan 28, 2016, at 9:28 AM, Jean-Baptiste Onofré wrote: > > Hi, > > the Beam proposal (initially Dataflow) was proposed last week.
Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen
HIV-1 mutates rapidly, making it difficult to design a vaccine that will protect people against all of the virus' iterations. A potential successful vaccine design might protect by eliciting broadly neutralizing antibodies (bNAbs), which target specific regions on HIV-1's trimeric envelope glycoprotein (Env) (see the Perspective by Mascola). Jardine et al.
Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen
A major goal of HIV-1 vaccine research is the design of immunogens capable of inducing broadly neutralizing antibodies (bnAbs) that bind to the viral envelope glycoprotein (Env). Poor binding of Env to unmutated precursors of bnAbs, including those of the VRC01-class, appears to be a major problem for bnAb induction. We engineered an immunogen that binds to VRC01-class bnAb precursors and immunized knock-in mice expressing germline-reverted VRC01 heavy chains.
[VOTE] Accept Groovy into the Apache Incubator
+1 Dan > On Mar 19, 2015, at 2:55 AM, Roman Shaposhnik <rvs@apache.org> wrote: > > Following the discussion earlier in the thread: > http://s.apache.org/KWE > > I would like to call a VOTE for accepting Groovy > as a new incubator project. > > The proposal is available at: > https://wiki.apache.org/incubator/GroovyProposal > and is also included at the bottom of this email.
[DISCUSS] Groovy Incubation proposal
> On Mar 12, 2015, at 8:51 AM, Bertrand Delacretaz <bdelacretaz@apache.org> wrote: > > On Thu, Mar 12, 2015 at 12:04 PM, Jochen Wiedmann > <jochen.wiedmann@gmail.com> wrote: >> ... I am quite certain, most Incubator members would accept a project to >> have a "vibrant community", if the project could show, for example,... > > Note that we don't care about the state of the community when entering > the incubator, that's an exit criteria.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Daniel
Contact Daniel, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack